The Shafafarmad vaccine belonging to the Imam Khomeini Executive Headquarters is the first Iranian vaccine to receive US Food and Drug Administration approval. In the one-day period announced for registration of participants in the human test of this vaccine, more than 9,000 people have announced their readiness to participate in the test.
Hojjat Niki Maleki, head of the Information Center of the Executive Headquarters of the Imam Command, tweeted that by 10:00 PM on Tuesday, January 23, 2010, 17,012 people had called 4030 to hear the conditions for participating in the clinical trials of the Corona Vaccine of the Executive Headquarters of the Imam Command. Of these, 9,911 announced their readiness to participate in the experiments.
The Iranian corona vaccine is scheduled to be injected into 56 people by the middle of next week. The vaccine will be tested first on one person, then on three people, and then on 56 volunteers. Participants in the clinical trial of the vaccine must be eligible, including between the ages of 18 and 50, with no history of chronic illness or allergic disease. Prior to vaccination, volunteers are tested for serology to check for antibodies in their bodies to make sure they do not have a history of coronary heart disease.
The vaccine will be given twice a week at intervals. In addition, volunteers are covered by insurance and given a gift.